Volume 31, Issue 12 (March 2021)
Studies in Medical Sciences 2021, 31(12): 956-964 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Faramarzpour M, Farhang Zand-Parsa A, Taslimi R, Hoseini M. Association between Nonalcoholic Fatty Liver Disease Based on Ultrasonography Indices and Severity of Coronary Artery Disease: A Cross-Sectional Study. Studies in Medical Sciences 2021; 31 (12) :956-964
URL: http://umj.umsu.ac.ir/article-1-5345-en.html
URL: http://umj.umsu.ac.ir/article-1-5345-en.html
Assistant Professor Department of Cardiology, Urmia University of Medical Sciences, Imam Khomeini Hospital Urmia, Iran (Corresponding Author) , faramarzpour.m94@gmail.com
Abstract: (3221 Views)
Background & Aims: Recent observations highlighted the importance of evaluating nonalcoholic fatty liver disease (NAFLD) in individuals with coronary artery disease (CAD) to establish strategies to prevent the evolution of the disease. However, the association between severity of CAD and NAFLD remains uncertain. The aim of this study was to investigate whether NAFLD was associated with severity of CAD assessed by coronary angiography.
Materials & Methods: This cross-sectional study was performed on 320 consecutive patients who were candidates for coronary angiography. All patients underwent coronary angiography to assess the presence and severity of coronary involvement and liver ultrasonography to assess the degree of fatty liver in the same session. The extension of CAD was measured using the Gensini score. The severity of NAFLD was measured using ultrasonography grading (Grade 0- III).
Results: Regarding grade of NAFLD, 42.2% of patients had normal condition (Grade 0), 31.5% had grade I, 19.7% had grade II, and 6.6% had grade III of NAFLD. With regard to the difference in grading of NAFLD between cardiovascular risk subgroups, this difference was only observed between the patients with BMI ≥ 30 kg/m2 and those with BMI < 30 kg/m2. The mean Gensini score in patients with normal condition (Grade 0) or grade I of NAFLD was 20.6 ± 1.2, in grade II of NAFLD was 23.6 ± 4.2, and in those with grade III of NAFLD was 47.3 ± 9.6. Findings indicate that CAD severity increases with the increase in the grade of NAFLD (p = 0.002). Using the multivariate linear regression model and with the presence of baseline variables as the confounders, the association between the Gensini score and NAFLD grade remained significant (p = 0.001).
Conclusion: The present study demonstrates a higher Gensini score in those patients with higher grades of NAFLD indicating a linear association between CAD severity and severity of NAFLD.
Materials & Methods: This cross-sectional study was performed on 320 consecutive patients who were candidates for coronary angiography. All patients underwent coronary angiography to assess the presence and severity of coronary involvement and liver ultrasonography to assess the degree of fatty liver in the same session. The extension of CAD was measured using the Gensini score. The severity of NAFLD was measured using ultrasonography grading (Grade 0- III).
Results: Regarding grade of NAFLD, 42.2% of patients had normal condition (Grade 0), 31.5% had grade I, 19.7% had grade II, and 6.6% had grade III of NAFLD. With regard to the difference in grading of NAFLD between cardiovascular risk subgroups, this difference was only observed between the patients with BMI ≥ 30 kg/m2 and those with BMI < 30 kg/m2. The mean Gensini score in patients with normal condition (Grade 0) or grade I of NAFLD was 20.6 ± 1.2, in grade II of NAFLD was 23.6 ± 4.2, and in those with grade III of NAFLD was 47.3 ± 9.6. Findings indicate that CAD severity increases with the increase in the grade of NAFLD (p = 0.002). Using the multivariate linear regression model and with the presence of baseline variables as the confounders, the association between the Gensini score and NAFLD grade remained significant (p = 0.001).
Conclusion: The present study demonstrates a higher Gensini score in those patients with higher grades of NAFLD indicating a linear association between CAD severity and severity of NAFLD.
Keywords: Metabolic Syndrome, Non-alcoholic fatty liver disease, Coronary artery disease, Gensini score
Type of Study: Research |
Subject:
قلب و عروق
References
1. Shaker M, Tabba A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities. World J Gastroenterol 2014;20(18):5320. [DOI:10.3748/wjg.v20.i18.5320] [PMID] [PMCID]
2. Ruhl C E, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment pharmacol ther 2015;41(1):65-76. [DOI:10.1111/apt.13012] [PMID]
3. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289 (22): 3000-4. [DOI:10.1001/jama.289.22.3000] [PMID]
4. Allocca M. Selmi C. Emerging nutritional treatments for nonalcoholic fatty liver disease. In Preedy VR; Lakshman R; Rajaskanthan RS. Nutr Diet Ther liver. CRC Press 2010; 131-46 [DOI:10.1201/9781420085501.ch9]
5. McCulough Arthur J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8 (3): 521-33. [DOI:10.1016/j.cld.2004.04.004] [PMID]
6. Vuppalanchi R, Chalasani N. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatol 2009; 49 (1): 306-17. [DOI:10.1002/hep.22603] [PMID] [PMCID]
7. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8. [DOI:10.7326/0003-4819-143-10-200511150-00009] [PMID]
8. Chen SH, He F, Zhou HL, Wu HR, Xia C, Li YM. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J Dig Dis 2011; 12: 125-30. [DOI:10.1111/j.1751-2980.2011.00487.x] [PMID]
9. Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 2118-23. [DOI:10.1111/j.1440-1746.2006.04698.x] [PMID]
10. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M,, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50. [DOI:10.2337/diabetes.50.8.1844] [PMID]
11. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J.Gastroenterol 2008; 14: 185-92. [DOI:10.3748/wjg.14.185] [PMID] [PMCID]
12. Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin. Liver Dis 2009; 13: 249-66. [DOI:10.1016/j.cld.2009.02.009] [PMID]
13. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13: 1579-84. [DOI:10.3748/wjg.v13.i10.1579] [PMID] [PMCID]
14. Targher G, Arcaro G.Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191: 235-40. [DOI:10.1016/j.atherosclerosis.2006.08.021] [PMID]
15. Mirbagheri S A, Abouzari M, Rashidi A. Independent association between sonographic fatty liver and ischemic heart disease confirmed by coronary angiography: preliminary results of an ongoing study. Gastroenterol 2007;132: A814-A.
16. Assy N, Djibre A, Farah R, Grosovsk M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010;254: 393-400. [DOI:10.1148/radiol.09090769] [PMID]
17. Akabame M, Hamaguchi K, Tomiyasu M, Tanaka Y, Kobayashi-Takenaka K,Nakano K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J 2008;72: 618-25. [DOI:10.1253/circj.72.618] [PMID]
18. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606. [DOI:10.1016/S0002-9149(83)80105-2]
19. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004;14:635-7. [DOI:10.1381/096089204323093408] [PMID]
20. Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, et al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol 2015;5(1):51-68. [DOI:10.1016/j.jceh.2015.02.006] [PMID] [PMCID]
21. Torun E, Aydın S, Gökçe S, Özgen İT, Donmez T, Cesur Y. Carotid intima-media thickness and flow-mediated dilation in obese children with non-alcoholic fatty liver disease. Turk J Gastroenterol 2014;25 Suppl 1:S92-8. [DOI:10.5152/tjg.2014.5552] [PMID]
22. Nahandi MZ, Khoshbaten M, Ramazanzadeh E, Abbaszadeh L, Javadrashid R, Shirazi KM, et al. Effect of non-alcoholic fatty liver disease on carotid artery intima-media thickness as a risk factor for atherosclerosis. Gastroenterol Hepatol Bed Bench 2014;7(1):55-62. [Google Scholar]
23. Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20(48):18070-91. [DOI:10.3748/wjg.v20.i48.18070] [PMID] [PMCID]
24. Abenavoli L, Peta V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014;9(3):134-40. [DOI:10.2174/1574887109666141216102458] [PMID]
25. Mellinger JL, Pencina KM, Massaro JM, Hoffmann U, Seshadri S, Fox CS, et al. Hepatic Steatosis and Cardiovascular Disease Outcomes: An Analysis of the Framingham Heart Study. J Hepatol 2015 ; S0168-8278(15):00167-1. [Google Scholar]
26. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 2015 ;62(3):773-83. [DOI:10.1002/hep.27869] [PMID] [PMCID]
27. Kwak MS, Yim JY, Kim D, Park MJ, Lim SH, Yang JI, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c. Diabetol Metab Syndr 2015;7:28. [DOI:10.1186/s13098-015-0025-4] [PMID] [PMCID]
28. Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 2012;35:2359-64. [DOI:10.2337/dc12-0515] [PMID] [PMCID]
29. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012;56:605-13. [DOI:10.1002/hep.25593] [PMID] [PMCID]
30. Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: an alarm for the heart? Liver Int 2007;27:891-4. [DOI:10.1111/j.1478-3231.2007.01531.x] [PMID]
31. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005;11:4838-42. [DOI:10.3748/wjg.v11.i31.4838] [PMID] [PMCID]
32. Chen CH, Nien CK, Yang CC, Yeh YH. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010;55:1752-60. [DOI:10.1007/s10620-009-0935-9] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
